Swedish Medical Center HIV Research StudiesAugust 30, 2004
Research Study for HIV-Positive Persons Failing Their Current Regimen48 week study of an experimental NNRTI in combination with other antiretroviral drugs in people who have resistance to protease inhibitors and NNRTIs.To qualify you must have:
For more information please call Heather at (206)-386-2820.
HIV Study for Multiply Treated People Who Are Failing Their Current RegimenStudy Drug: An investigational protease inhibitor with a combination of other drugs.Length: 96 weeks. Study related lab tests, including genotyping and physical exams are free. The investigational drug is provided at no cost. Reimbursement for childcare and transportation are possible. Will work around your schedule (evenings, weekends, etc.). For more information please call Janice at (206)-386-2523.
Tipranavir Early Access ProgramA limited number of spaces in the Tipranavir early access program are available to persons with private providers and through the Madison Clinic. Patients must have a CD4 count <100 copies/mm3.For more information please call Heather at (206)-386-2820.
Protease Inhibitor Switch StudySwedish Medical Center is looking for HIV+ people to participate in a research study that will replace Kaletra® with a currently marked protease inhibitor to see if it will improve cholesterol levels. To take part in this study, your current viral load must be <50 copies/mL. This is a 48-week trial that includes:
For more information please call Heather (206)-386-2820.
HIV Study for People Who Have Never Been Treated for HIVStudy Drug: Kaletra vs. Amprenavir/ritonavir with abacavir and 3TC.Length: 48 weeks. Study-related lab tests, physical exams and study medications are free. Reimbursement for childcare and transportation are possible. Will work around your schedule (evenings, weekends, etc.). For more information please call Janice at: (206)-386-2523.
HIV Study for People Who Have Taken an HIV Medication Called a Non-Nucleoside Reverse InhibitorThis is a study to test multiple doses of a potential new investigational drug when it is given over 7 days.For more information please call Janice at: (206)-386-2523.
This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.
|